Business Context and Reporting Period
Company: BioCryst Pharmaceuticals, Inc. (BCRX)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Three months ended March 31, 2026
Business Overview: BioCryst is a global biotechnology company focused on developing and commercializing medicines for hereditary angioedema (HAE) and other rare diseases. Its primary commercial product is ORLADEYO® (berotralstat). The company operates as a single reportable segment.
Key Financial Metrics
| Metric (in thousands) | Q1 2026 | Q1 2025 |
|---|---|---|
| Total Revenues | $156,413 | $145,534 |
| Net (Loss) Income | $(721,812) | $32 |
| Diluted EPS | $(2.98) | $0.00 |
| Operating Cash Flow | $(61,791) | $(27,517) |
| Cash & Cash Equivalents (End of Period) | $171,591 | $105,190 |
| Total Debt (Secured Term Loan) | $395,197 | $0 |
| Royalty Financing Obligations | $447,498 | $465,688 |
Note: The Q1 2026 net loss includes a significant non-cash charge of $697.8 million for acquired in-process research and development (IPR&D) related to the Astria Therapeutics acquisition.
Material Changes vs. Prior Period
- Acquisition of Astria Therapeutics: On January 23, 2026, BioCryst completed the acquisition of Astria Therapeutics, Inc. for a total purchase price of approximately $874.3 million (comprising $251.7 million in equity and $608.6 million in cash). This transaction added the lead product candidate navenibart and STAR-0310 to the pipeline.
- Revenue Growth: Total revenues increased 7.5% to $156.4 million, driven by a $25.6 million increase in ORLADEYO revenue (excluding European business) due to strong patient demand and net price increases. This was partially offset by the loss of European ORLADEYO revenue following the sale of that business in October 2025.
- Expense Surge: Operating expenses increased significantly to $858.0 million from $124.3 million. The primary driver was the $697.8 million IPR&D expense for navenibart. Additionally, R&D and SG&A expenses increased due to integration costs, stock option payouts, and separation costs associated with the Astria merger.
- Debt Financing: To fund the cash portion of the Astria acquisition, the company entered into a $400 million secured term loan with Blackstone (the "Blackstone Loan Agreement") in January 2026. This replaced the previous Pharmakon Loan Agreement, which was paid off in 2025.
- European Business Sale: The company sold its European ORLADEYO business to Neopharmed Gentili S.p.A. on October 1, 2025. Consequently, Q1 2026 results do not include European ORLADEYO revenues or associated operating expenses, though the company retains royalty rights.
Guidance, Outlook, and Risks
- Liquidity: Management believes current financial resources (approximately $259 million in cash and investments as of March 31, 2026) are sufficient to fund operations for at least the next 12 months.
- Pipeline Updates:
- Navenibart: Positive interim results from the ALPHA-SOLAR trial showed sustained HAE attack suppression. Patient enrollment in the pivotal ALPHA-ORBIT study is on track for completion by June 2026. A licensing agreement for European commercialization was signed in May 2026 (subsequent event) with a $70 million upfront payment.
- ORLADEYO: A manufacturing issue identified in May 2026 may delay the initial fulfillment of the new oral pellet formulation for pediatric patients.
- BCX17725: Dosing began in Part 4 of the Phase 1 trial for Netherton syndrome.
- Avoralstat: Development was discontinued in Q1 2026 to focus on rare diseases.
- Key Risks:
- Patent Litigation: The company is defending against a Paragraph IV certification from Annora Pharma regarding generic versions of ORLADEYO. Litigation is ongoing in the District of Delaware.
- Debt Covenants: The Blackstone Loan Agreement includes restrictive covenants, including a minimum liquidity covenant, and is secured by substantially all company assets.
- Merger Integration: Risks associated with integrating Astria's operations and realizing anticipated synergies.
Investor Verification Checklist
- IPR&D Accounting: Verify the valuation assumptions and fair value allocation for the $697.8 million navenibart IPR&D charge, as this is a non-cash item that significantly distorts GAAP profitability.
- Debt Service Capacity: Assess the company's ability to meet interest-only payments on the new $400 million Blackstone term loan and ongoing royalty financing obligations to RPI and OMERS.
- ORLADEYO Manufacturing: Monitor the resolution of the manufacturing issue affecting the pediatric oral pellet formulation and its potential impact on future revenue growth.
- Patent Litigation Status: Track the progress of the patent infringement lawsuit against Annora Pharma, as a loss could expose the core revenue stream to generic competition.
- Merger Synergies: Evaluate the timeline and cost realization for the integration of Astria Therapeutics, specifically regarding the commercialization of navenibart.